APO Research
Talk to an analyst

APO RESEARCH · REPORT

Retinal Drugs and Biologics

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Retinal Drugs and Biologics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025195 pages

Choose your research edition.

Industry ResearchRetinal Drugs and Biologics Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Retinal Drugs and Biologics Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Retinal Drugs and Biologics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Retinal Drugs and Biologics Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Retinal Drugs and Biologics Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Retinal Drugs and Biologics market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Retinal Drugs and Biologics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Retinal Drugs and Biologics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Retinal Drugs and Biologics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Retinal Drugs and Biologics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Retinal Drugs and Biologics include ALLERGAN, Alimera Sciences, Bausch & Lomb, Bristol-Myers Squibb, Genentech, Genzyme, Janssen Biotech, OCULAR THERAPEUTIX and Swedish Orphan Biovitrum, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Retinal Drugs and Biologics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Retinal Drugs and Biologics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Retinal Drugs and Biologics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Retinal Drugs and Biologics market size, projected growth trends, production technologies, key applications, and end-use industries.

Retinal Drugs and Biologics Segment by Company

ALLERGAN

Alimera Sciences

Bausch & Lomb

Bristol-Myers Squibb

Genentech

Genzyme

Janssen Biotech

OCULAR THERAPEUTIX

Swedish Orphan Biovitrum

UCBCares

AbbVie

Roche

Retinal Drugs and Biologics Segment by Type

Ocular Inflammatory Disease (Uveitis)

Diabetic Retinopathy

Age Related Macular Degeneration

Macular Hole

Retinal Drugs and Biologics Segment by Application

Hospitals

Clinics

Others

Retinal Drugs and Biologics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Retinal Drugs and Biologics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Retinal Drugs and Biologics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Retinal Drugs and Biologics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Retinal Drugs and Biologics market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Retinal Drugs and Biologics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Retinal Drugs and Biologics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Retinal Drugs and Biologics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Retinal Drugs and Biologics Industry Trends Table 2. Retinal Drugs and Biologics Industry Drivers Table 3. Retinal Drugs and Biologics Industry Opportunities and Challenges Table 4. Retinal Drugs and Biologics Industry Restraints Table 5. Global Retinal Drugs and Biologics Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Retinal Drugs and Biologics Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Retinal Drugs and Biologics Sales by Manufacturers (k tons) & (2021-2026) Table 8. Global Retinal Drugs and Biologics Sales Market Share by Manufacturers Table 9. Global Retinal Drugs and Biologics Average Sales Price (US$/ton) of Manufacturers (2021-2026) Table 10. Global Retinal Drugs and Biologics Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Retinal Drugs and Biologics Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Retinal Drugs and Biologics Manufacturers, Product Type & Application Table 13. Global Retinal Drugs and Biologics Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Retinal Drugs and Biologics by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Ocular Inflammatory Disease (Uveitis) Table 17. Major Manufacturers of Diabetic Retinopathy Table 18. Major Manufacturers of Age Related Macular Degeneration Table 19. Major Manufacturers of Macular Hole Table 20. Global Retinal Drugs and Biologics Sales by Type 2021 VS 2025 VS 2032 (k tons) Table 21. Global Retinal Drugs and Biologics Sales by Type (2021-2026) & (k tons) Table 22. Global Retinal Drugs and Biologics Sales by Type (2027-2032) & (k tons) Table 23. Global Retinal Drugs and Biologics Sales Market Share by Type (2021-2026) Table 24. Global Retinal Drugs and Biologics Sales Market Share by Type (2027-2032) Table 25. Global Retinal Drugs and Biologics Revenue by Type 2021 VS 2025 VS 2032 (k tons) Table 26. Global Retinal Drugs and Biologics Revenue by Type (2021-2026) & (k tons) Table 27. Global Retinal Drugs and Biologics Revenue by Type (2027-2032) & (k tons) Table 28. Global Retinal Drugs and Biologics Revenue Market Share by Type (2021-2026) Table 29. Global Retinal Drugs and Biologics Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Hospitals Table 31. Major Manufacturers of Clinics Table 32. Major Manufacturers of Others Table 33. Global Retinal Drugs and Biologics Sales by Application 2021 VS 2025 VS 2032 (k tons) Table 34. Global Retinal Drugs and Biologics Sales by Application (2021-2026) & (k tons) Table 35. Global Retinal Drugs and Biologics Sales by Application (2027-2032) & (k tons) Table 36. Global Retinal Drugs and Biologics Sales Market Share by Application (2021-2026) Table 37. Global Retinal Drugs and Biologics Sales Market Share by Application (2027-2032) Table 38. Global Retinal Drugs and Biologics Revenue by Application 2021 VS 2025 VS 2032 (k tons) Table 39. Global Retinal Drugs and Biologics Revenue by Application (2021-2026) & (k tons) Table 40. Global Retinal Drugs and Biologics Revenue by Application (2027-2032) & (k tons) Table 41. Global Retinal Drugs and Biologics Revenue Market Share by Application (2021-2026) Table 42. Global Retinal Drugs and Biologics Revenue Market Share by Application (2027-2032) Table 43. Global Retinal Drugs and Biologics Sales by Region: 2021 VS 2025 VS 2032 (k tons) Table 44. Global Retinal Drugs and Biologics Sales by Region (2021-2026) & (k tons) Table 45. Global Retinal Drugs and Biologics Sales Market Share by Region (2021-2026) Table 46. Global Retinal Drugs and Biologics Sales Forecasted by Region (2027-2032) & (k tons) Table 47. Global Retinal Drugs and Biologics Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Retinal Drugs and Biologics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 49. North America Retinal Drugs and Biologics Sales by Country (2021-2026) & (k tons) Table 50. North America Retinal Drugs and Biologics Sales by Country (2027-2032) & (k tons) Table 51. Europe Retinal Drugs and Biologics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 52. Europe Retinal Drugs and Biologics Sales by Country (2021-2026) & (k tons) Table 53. Europe Retinal Drugs and Biologics Sales by Country (2027-2032) & (k tons) Table 54. Asia Pacific Retinal Drugs and Biologics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 55. Asia Pacific Retinal Drugs and Biologics Sales by Country (2021-2026) & (k tons) Table 56. Asia Pacific Retinal Drugs and Biologics Sales by Country (2027-2032) & (k tons) Table 57. South America, Middle East and Africa Retinal Drugs and Biologics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 58. South America, Middle East and Africa Retinal Drugs and Biologics Sales by Country (2021-2026) & (k tons) Table 59. South America, Middle East and Africa Retinal Drugs and Biologics Sales by Country (2027-2032) & (k tons) Table 60. Global Retinal Drugs and Biologics Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Retinal Drugs and Biologics Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Retinal Drugs and Biologics Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Retinal Drugs and Biologics Revenue Market Share by Region (2021-2026) Table 64. Global Retinal Drugs and Biologics Revenue Market Share by Region (2027-2032) Table 65. ALLERGAN Company Information Table 66. ALLERGAN Business Overview Table 67. ALLERGAN Retinal Drugs and Biologics Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. ALLERGAN Retinal Drugs and Biologics Product Portfolio Table 69. ALLERGAN Recent Development Table 70. Alimera Sciences Company Information Table 71. Alimera Sciences Business Overview Table 72. Alimera Sciences Retinal Drugs and Biologics Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Alimera Sciences Retinal Drugs and Biologics Product Portfolio Table 74. Alimera Sciences Recent Development Table 75. Bausch & Lomb Company Information Table 76. Bausch & Lomb Business Overview Table 77. Bausch & Lomb Retinal Drugs and Biologics Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Bausch & Lomb Retinal Drugs and Biologics Product Portfolio Table 79. Bausch & Lomb Recent Development Table 80. Bristol-Myers Squibb Company Information Table 81. Bristol-Myers Squibb Business Overview Table 82. Bristol-Myers Squibb Retinal Drugs and Biologics Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Bristol-Myers Squibb Retinal Drugs and Biologics Product Portfolio Table 84. Bristol-Myers Squibb Recent Development Table 85. Genentech Company Information Table 86. Genentech Business Overview Table 87. Genentech Retinal Drugs and Biologics Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Genentech Retinal Drugs and Biologics Product Portfolio Table 89. Genentech Recent Development Table 90. Genzyme Company Information Table 91. Genzyme Business Overview Table 92. Genzyme Retinal Drugs and Biologics Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Genzyme Retinal Drugs and Biologics Product Portfolio Table 94. Genzyme Recent Development Table 95. Janssen Biotech Company Information Table 96. Janssen Biotech Business Overview Table 97. Janssen Biotech Retinal Drugs and Biologics Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Janssen Biotech Retinal Drugs and Biologics Product Portfolio Table 99. Janssen Biotech Recent Development Table 100. OCULAR THERAPEUTIX Company Information Table 101. OCULAR THERAPEUTIX Business Overview Table 102. OCULAR THERAPEUTIX Retinal Drugs and Biologics Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. OCULAR THERAPEUTIX Retinal Drugs and Biologics Product Portfolio Table 104. OCULAR THERAPEUTIX Recent Development Table 105. Swedish Orphan Biovitrum Company Information Table 106. Swedish Orphan Biovitrum Business Overview Table 107. Swedish Orphan Biovitrum Retinal Drugs and Biologics Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Swedish Orphan Biovitrum Retinal Drugs and Biologics Product Portfolio Table 109. Swedish Orphan Biovitrum Recent Development Table 110. UCBCares Company Information Table 111. UCBCares Business Overview Table 112. UCBCares Retinal Drugs and Biologics Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. UCBCares Retinal Drugs and Biologics Product Portfolio Table 114. UCBCares Recent Development Table 115. AbbVie Company Information Table 116. AbbVie Business Overview Table 117. AbbVie Retinal Drugs and Biologics Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. AbbVie Retinal Drugs and Biologics Product Portfolio Table 119. AbbVie Recent Development Table 120. Roche Company Information Table 121. Roche Business Overview Table 122. Roche Retinal Drugs and Biologics Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Roche Retinal Drugs and Biologics Product Portfolio Table 124. Roche Recent Development Table 125. Key Raw Materials Table 126. Raw Materials Key Suppliers Table 127. Retinal Drugs and Biologics Distributors List Table 128. Retinal Drugs and Biologics Customers List Table 129. Research Programs/Design for This Report Table 130. Authors List of This Report Table 131. Secondary Sources Table 132. Primary Sources List of Figures Figure 1. Retinal Drugs and Biologics Product Image Figure 2. Global Retinal Drugs and Biologics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Retinal Drugs and Biologics Market Size (2021-2032) & (US$ Million) Figure 4. Global Retinal Drugs and Biologics Sales (2021-2032) & (k tons) Figure 5. Global Retinal Drugs and Biologics Average Price (US$/ton) & (2021-2032) Figure 6. Global Top 5 and 10 Retinal Drugs and Biologics Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Ocular Inflammatory Disease (Uveitis) Image Figure 9. Diabetic Retinopathy Image Figure 10. Age Related Macular Degeneration Image Figure 11. Macular Hole Image Figure 12. Global Retinal Drugs and Biologics Sales by Type (2021 VS 2025 VS 2032) & (k tons) Figure 13. Global Retinal Drugs and Biologics Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Retinal Drugs and Biologics Sales Market Share by Type (2021-2032) Figure 15. Global Retinal Drugs and Biologics Revenue by Type (2021 VS 2025 VS 2032) & (k tons) Figure 16. Global Retinal Drugs and Biologics Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Retinal Drugs and Biologics Revenue Market Share by Type (2021-2032) Figure 18. Hospitals Image Figure 19. Clinics Image Figure 20. Others Image Figure 21. Global Retinal Drugs and Biologics Sales by Application (2021 VS 2025 VS 2032) & (k tons) Figure 22. Global Retinal Drugs and Biologics Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Retinal Drugs and Biologics Sales Market Share by Application (2021-2032) Figure 24. Global Retinal Drugs and Biologics Revenue by Application (2021 VS 2025 VS 2032) & (k tons) Figure 25. Global Retinal Drugs and Biologics Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Retinal Drugs and Biologics Revenue Market Share by Application (2021-2032) Figure 27. North America Retinal Drugs and Biologics Sales and Growth Rate (2021-2032) & (k tons) Figure 28. North America Retinal Drugs and Biologics Sales Market Share by Country (2021-2032) Figure 29. U.S. Retinal Drugs and Biologics Sales and Growth Rate (2021-2032) & (k tons) Figure 30. Canada Retinal Drugs and Biologics Sales and Growth Rate (2021-2032) & (k tons) Figure 31. Mexico Retinal Drugs and Biologics Sales and Growth Rate (2021-2032) & (k tons) Figure 32. Europe Retinal Drugs and Biologics Sales and Growth Rate (2021-2032) & (k tons) Figure 33. Europe Retinal Drugs and Biologics Sales Market Share by Country (2021-2032) Figure 34. Germany Retinal Drugs and Biologics Sales and Growth Rate (2021-2032) & (k tons) Figure 35. France Retinal Drugs and Biologics Sales and Growth Rate (2021-2032) & (k tons) Figure 36. U.K. Retinal Drugs and Biologics Sales and Growth Rate (2021-2032) & (k tons) Figure 37. Italy Retinal Drugs and Biologics Sales and Growth Rate (2021-2032) & (k tons) Figure 38. Netherlands Retinal Drugs and Biologics Sales and Growth Rate (2021-2032) & (k tons) Figure 39. Asia Pacific Retinal Drugs and Biologics Sales and Growth Rate (2021-2032) & (k tons) Figure 40. Asia Pacific Retinal Drugs and Biologics Sales Market Share by Country (2021-2032) Figure 41. China Retinal Drugs and Biologics Sales and Growth Rate (2021-2032) & (k tons) Figure 42. Japan Retinal Drugs and Biologics Sales and Growth Rate (2021-2032) & (k tons) Figure 43. South Korea Retinal Drugs and Biologics Sales and Growth Rate (2021-2032) & (k tons) Figure 44. Southeast Asia Retinal Drugs and Biologics Sales and Growth Rate (2021-2032) & (k tons) Figure 45. India Retinal Drugs and Biologics Sales and Growth Rate (2021-2032) & (k tons) Figure 46. Australia Retinal Drugs and Biologics Sales and Growth Rate (2021-2032) & (k tons) Figure 47. South America, Middle East and Africa Retinal Drugs and Biologics Sales and Growth Rate (2021-2032) & (k tons) Figure 48. South America, Middle East and Africa Retinal Drugs and Biologics Sales Market Share by Country (2021-2032) Figure 49. Brazil Retinal Drugs and Biologics Sales and Growth Rate (2021-2032) & (k tons) Figure 50. South Africa Retinal Drugs and Biologics Sales and Growth Rate (2021-2032) & (k tons) Figure 51. Saudi Arabia Retinal Drugs and Biologics Sales and Growth Rate (2021-2032) & (k tons) Figure 52. Turkey Retinal Drugs and Biologics Sales and Growth Rate (2021-2032) & (k tons) Figure 53. Argentina Retinal Drugs and Biologics Sales and Growth Rate (2021-2032) & (k tons) Figure 54. UAE Retinal Drugs and Biologics Sales and Growth Rate (2021-2032) & (k tons) Figure 55. Egypt Retinal Drugs and Biologics Sales and Growth Rate (2021-2032) & (k tons) Figure 56. Chile Retinal Drugs and Biologics Sales and Growth Rate (2021-2032) & (k tons) Figure 57. Global Retinal Drugs and Biologics Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Retinal Drugs and Biologics Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Retinal Drugs and Biologics Revenue (2021-2032) & (US$ Million) Figure 60. North America Retinal Drugs and Biologics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Retinal Drugs and Biologics Revenue (2021-2032) & (US$ Million) Figure 62. Europe Retinal Drugs and Biologics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Retinal Drugs and Biologics Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Retinal Drugs and Biologics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Retinal Drugs and Biologics Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Retinal Drugs and Biologics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Retinal Drugs and Biologics Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Retinal Drugs and Biologics Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Ocular Inflammatory Disease (Uveitis)
  • Diabetic Retinopathy
  • Age Related Macular Degeneration
  • Macular Hole
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • ALLERGAN
  • Alimera Sciences
  • Bausch & Lomb
  • Bristol-Myers Squibb
  • Genentech
  • Genzyme
  • Janssen Biotech
  • OCULAR THERAPEUTIX
  • Swedish Orphan Biovitrum
  • UCBCares
  • AbbVie
  • Roche

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Retinal Drugs and Biologics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Retinal Drugs and Biologics Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Retinal Drugs and Biologics Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Retinal Drugs and Biologics Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Retinal Drugs and Biologics Market Dynamics
  1. 2.1 Retinal Drugs and Biologics Industry Trends
  2. 2.2 Retinal Drugs and Biologics Industry Drivers
  3. 2.3 Retinal Drugs and Biologics Industry Opportunities and Challenges
  4. 2.4 Retinal Drugs and Biologics Industry Restraints
3 Retinal Drugs and Biologics Market by Manufacturers
  1. 3.1 Global Retinal Drugs and Biologics Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Retinal Drugs and Biologics Sales by Manufacturers (2021-2026)
  3. 3.3 Global Retinal Drugs and Biologics Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Retinal Drugs and Biologics Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Retinal Drugs and Biologics Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Retinal Drugs and Biologics Manufacturers, Product Type & Application
  7. 3.7 Global Retinal Drugs and Biologics Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Retinal Drugs and Biologics Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Retinal Drugs and Biologics Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Retinal Drugs and Biologics Tier 1, Tier 2, and Tier 3
4 Retinal Drugs and Biologics Market by Type
  1. 4.1 Retinal Drugs and Biologics Type Introduction
  2. 4.1.1 Ocular Inflammatory Disease (Uveitis)
  3. 4.1.2 Diabetic Retinopathy
  4. 4.1.3 Age Related Macular Degeneration
  5. 4.1.4 Macular Hole
  6. 4.2 Global Retinal Drugs and Biologics Sales by Type
  7. 4.2.1 Global Retinal Drugs and Biologics Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Retinal Drugs and Biologics Sales by Type (2021-2032)
  9. 4.2.3 Global Retinal Drugs and Biologics Sales Market Share by Type (2021-2032)
  10. 4.3 Global Retinal Drugs and Biologics Revenue by Type
  11. 4.3.1 Global Retinal Drugs and Biologics Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Retinal Drugs and Biologics Revenue by Type (2021-2032)
  13. 4.3.3 Global Retinal Drugs and Biologics Revenue Market Share by Type (2021-2032)
5 Retinal Drugs and Biologics Market by Application
  1. 5.1 Retinal Drugs and Biologics Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Retinal Drugs and Biologics Sales by Application
  6. 5.2.1 Global Retinal Drugs and Biologics Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Retinal Drugs and Biologics Sales by Application (2021-2032)
  8. 5.2.3 Global Retinal Drugs and Biologics Sales Market Share by Application (2021-2032)
  9. 5.3 Global Retinal Drugs and Biologics Revenue by Application
  10. 5.3.1 Global Retinal Drugs and Biologics Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Retinal Drugs and Biologics Revenue by Application (2021-2032)
  12. 5.3.3 Global Retinal Drugs and Biologics Revenue Market Share by Application (2021-2032)
6 Global Retinal Drugs and Biologics Sales by Region
  1. 6.1 Global Retinal Drugs and Biologics Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Retinal Drugs and Biologics Sales by Region (2021-2032)
  3. 6.2.1 Global Retinal Drugs and Biologics Sales by Region (2021-2026)
  4. 6.2.2 Global Retinal Drugs and Biologics Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Retinal Drugs and Biologics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Retinal Drugs and Biologics Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Retinal Drugs and Biologics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Retinal Drugs and Biologics Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Retinal Drugs and Biologics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Retinal Drugs and Biologics Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Retinal Drugs and Biologics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Retinal Drugs and Biologics Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Retinal Drugs and Biologics Revenue by Region
  1. 7.1 Global Retinal Drugs and Biologics Revenue by Region
  2. 7.1.1 Global Retinal Drugs and Biologics Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Retinal Drugs and Biologics Revenue by Region (2021-2026)
  4. 7.1.3 Global Retinal Drugs and Biologics Revenue by Region (2027-2032)
  5. 7.1.4 Global Retinal Drugs and Biologics Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Retinal Drugs and Biologics Revenue (2021-2032)
  8. 7.2.2 North America Retinal Drugs and Biologics Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Retinal Drugs and Biologics Revenue (2021-2032)
  11. 7.3.2 Europe Retinal Drugs and Biologics Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Retinal Drugs and Biologics Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Retinal Drugs and Biologics Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Retinal Drugs and Biologics Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Retinal Drugs and Biologics Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 ALLERGAN
  2. 8.1.1 ALLERGAN Company Information
  3. 8.1.2 ALLERGAN Business Overview
  4. 8.1.3 ALLERGAN Retinal Drugs and Biologics Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 ALLERGAN Retinal Drugs and Biologics Product Portfolio
  6. 8.1.5 ALLERGAN Recent Developments
  7. 8.2 Alimera Sciences
  8. 8.2.1 Alimera Sciences Company Information
  9. 8.2.2 Alimera Sciences Business Overview
  10. 8.2.3 Alimera Sciences Retinal Drugs and Biologics Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Alimera Sciences Retinal Drugs and Biologics Product Portfolio
  12. 8.2.5 Alimera Sciences Recent Developments
  13. 8.3 Bausch & Lomb
  14. 8.3.1 Bausch & Lomb Company Information
  15. 8.3.2 Bausch & Lomb Business Overview
  16. 8.3.3 Bausch & Lomb Retinal Drugs and Biologics Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bausch & Lomb Retinal Drugs and Biologics Product Portfolio
  18. 8.3.5 Bausch & Lomb Recent Developments
  19. 8.4 Bristol-Myers Squibb
  20. 8.4.1 Bristol-Myers Squibb Company Information
  21. 8.4.2 Bristol-Myers Squibb Business Overview
  22. 8.4.3 Bristol-Myers Squibb Retinal Drugs and Biologics Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bristol-Myers Squibb Retinal Drugs and Biologics Product Portfolio
  24. 8.4.5 Bristol-Myers Squibb Recent Developments
  25. 8.5 Genentech
  26. 8.5.1 Genentech Company Information
  27. 8.5.2 Genentech Business Overview
  28. 8.5.3 Genentech Retinal Drugs and Biologics Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Genentech Retinal Drugs and Biologics Product Portfolio
  30. 8.5.5 Genentech Recent Developments
  31. 8.6 Genzyme
  32. 8.6.1 Genzyme Company Information
  33. 8.6.2 Genzyme Business Overview
  34. 8.6.3 Genzyme Retinal Drugs and Biologics Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Genzyme Retinal Drugs and Biologics Product Portfolio
  36. 8.6.5 Genzyme Recent Developments
  37. 8.7 Janssen Biotech
  38. 8.7.1 Janssen Biotech Company Information
  39. 8.7.2 Janssen Biotech Business Overview
  40. 8.7.3 Janssen Biotech Retinal Drugs and Biologics Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Janssen Biotech Retinal Drugs and Biologics Product Portfolio
  42. 8.7.5 Janssen Biotech Recent Developments
  43. 8.8 OCULAR THERAPEUTIX
  44. 8.8.1 OCULAR THERAPEUTIX Company Information
  45. 8.8.2 OCULAR THERAPEUTIX Business Overview
  46. 8.8.3 OCULAR THERAPEUTIX Retinal Drugs and Biologics Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 OCULAR THERAPEUTIX Retinal Drugs and Biologics Product Portfolio
  48. 8.8.5 OCULAR THERAPEUTIX Recent Developments
  49. 8.9 Swedish Orphan Biovitrum
  50. 8.9.1 Swedish Orphan Biovitrum Company Information
  51. 8.9.2 Swedish Orphan Biovitrum Business Overview
  52. 8.9.3 Swedish Orphan Biovitrum Retinal Drugs and Biologics Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Swedish Orphan Biovitrum Retinal Drugs and Biologics Product Portfolio
  54. 8.9.5 Swedish Orphan Biovitrum Recent Developments
  55. 8.10 UCBCares
  56. 8.10.1 UCBCares Company Information
  57. 8.10.2 UCBCares Business Overview
  58. 8.10.3 UCBCares Retinal Drugs and Biologics Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 UCBCares Retinal Drugs and Biologics Product Portfolio
  60. 8.10.5 UCBCares Recent Developments
  61. 8.11 AbbVie
  62. 8.11.1 AbbVie Company Information
  63. 8.11.2 AbbVie Business Overview
  64. 8.11.3 AbbVie Retinal Drugs and Biologics Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 AbbVie Retinal Drugs and Biologics Product Portfolio
  66. 8.11.5 AbbVie Recent Developments
  67. 8.12 Roche
  68. 8.12.1 Roche Company Information
  69. 8.12.2 Roche Business Overview
  70. 8.12.3 Roche Retinal Drugs and Biologics Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Roche Retinal Drugs and Biologics Product Portfolio
  72. 8.12.5 Roche Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Retinal Drugs and Biologics Value Chain Analysis
  2. 9.1.1 Retinal Drugs and Biologics Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Retinal Drugs and Biologics Production Mode & Process
  6. 9.2 Retinal Drugs and Biologics Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Retinal Drugs and Biologics Distributors
  9. 9.2.3 Retinal Drugs and Biologics Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst